Teva draws line under asthma inhaler feud with US rival

Settlement ends expectations of SCOTUS petition | Federal Circuit stipulates patents must explicitly claim the active ingredient of a drug to qualify for Orange Book listing | FTC backs Amneal, saying ‘improper listings’ stifle generic competition.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva can’t revive Orange book inhaler battle at Fed Circ

4 March 2025 Federal Circuit says only patents claiming the active ingredient of a drug are eligible for listing | Injunction against Teva temporarily paused in January pending the appeal court’s decision to review.

Americas

Fed Circ grants Teva temporary pause in Orange Book feud

23 January 2025 Teva insisted panel’s narrow interpretation of ‘claims the drug’ will have a seismic effect on the Orange Book | Stay granted while en banc rehearing is under question | Decision could reshape patent listing standards and impact the availability of generic drugs.

Americas

Fed Circ orders Teva to delist five patents from Orange Book

24 December 2024 Dispute stems from Amneal’s efforts to market generic version of Teva’s inhaler for treating asthma | Precedential decision could restrict how brand-name pharmaceutical companies use the Orange Book to extend market exclusivity.